- Home
- SVCC vs TLSI Comparison
SVCC vs TLSI Comparison
Compare SVCC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVCC
- TLSI
- Stock Information
- Founded
- SVCC 2024
- TLSI 2010
- Country
- SVCC United States
- TLSI United States
- Employees
- SVCC N/A
- TLSI N/A
- Industry
- SVCC
- TLSI Medical Specialities
- Sector
- SVCC
- TLSI Health Care
- Exchange
- SVCC Nasdaq
- TLSI Nasdaq
- Market Cap
- SVCC 218.3M
- TLSI 204.0M
- IPO Year
- SVCC 2025
- TLSI N/A
- Fundamental
- Price
- SVCC N/A
- TLSI $5.07
- Analyst Decision
- SVCC
- TLSI Strong Buy
- Analyst Count
- SVCC 0
- TLSI 5
- Target Price
- SVCC N/A
- TLSI $10.90
- AVG Volume (30 Days)
- SVCC 18.9K
- TLSI 154.9K
- Earning Date
- SVCC 01-01-0001
- TLSI 08-13-2025
- Dividend Yield
- SVCC N/A
- TLSI N/A
- EPS Growth
- SVCC N/A
- TLSI N/A
- EPS
- SVCC N/A
- TLSI N/A
- Revenue
- SVCC N/A
- TLSI $32,141,000.00
- Revenue This Year
- SVCC N/A
- TLSI $55.52
- Revenue Next Year
- SVCC N/A
- TLSI $54.76
- P/E Ratio
- SVCC N/A
- TLSI N/A
- Revenue Growth
- SVCC N/A
- TLSI 46.20
- 52 Week Low
- SVCC $9.95
- TLSI $3.50
- 52 Week High
- SVCC $10.31
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- SVCC N/A
- TLSI 45.72
- Support Level
- SVCC N/A
- TLSI $4.81
- Resistance Level
- SVCC N/A
- TLSI $5.63
- Average True Range (ATR)
- SVCC 0.00
- TLSI 0.35
- MACD
- SVCC 0.00
- TLSI -0.03
- Stochastic Oscillator
- SVCC 0.00
- TLSI 30.95
About SVCC Stellar V Capital Corp. Class A Ordinary Shares
Stellar V Capital Corp is a blank check company.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.